Collegium Pharmaceutical, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belanger from Needham maintained a Buy rating on the stock and has a $46.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Serge Belanger has given his Buy rating due to a combination of factors that highlight Collegium Pharmaceutical’s strong financial performance and strategic initiatives. The company reported a robust second quarter in 2025, with revenues surpassing expectations at $188 million, marking a 6% increase quarter-over-quarter and a 29% increase year-over-year. This growth was primarily driven by the impressive sales of Xtampza, which benefited from favorable conditions such as a one-time rebate and improved gross-to-net adjustments.
Additionally, the focus on Jornay PM as a key growth driver in the second half of 2025 is significant. The expansion of the sales force and enhanced marketing efforts are expected to boost Jornay PM’s performance, especially during the back-to-school period. The company’s decision to raise its sales guidance for Jornay PM reflects confidence in its market potential. Furthermore, the current stock valuation does not fully reflect the company’s growth prospects, profitability, and successful track record in acquisitions and integrations, justifying the Buy rating and a price target of $46.
Belanger covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, NewAmsterdam Pharma Company, and BioCryst. According to TipRanks, Belanger has an average return of 2.8% and a 44.00% success rate on recommended stocks.
In another report released today, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $33.00 price target.